ROC-325 NEW
| Price | $30 | $47 | $78 |
| Package | 2mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-05-11 |
Product Details
| Product Name: ROC-325 | CAS No.: 1859141-26-6 |
| Purity: 99.68% | Supply Ability: 10g |
| Release date: 2026/05/11 |
Product Introduction
Bioactivity
| Name | ROC-325 |
| Description | ROC-325 is an effective and orally active inhibitor of autophagy with anticancer activity. ROC-325 induces renal cell carcinoma apoptosis and exhibits favorable selectivity. |
| In vitro | ROC-325 (5 μM) leads to the formation of LC3B punctae and a robust increase in LC3B levels in both A498 and 786-0 RCC cells. ROC-325 promotes a dose-dependent increase in LC3B expression in a manner that correlated with a corresponding increase in the levels of p62 and cathepsin D. ROC-325 inhibits cells growth with IC50 values of 4.9 μM, 11 μM, 4.6 μM, 5.4 μM, 7.4 μM, 11 μM, 8.2 μM, 5.8 μM, 5.0 μM, 11 μM, 8.4 μM and 6.0 μM for A498, A549, CFPAC-1, COLO-205, DLD-1, IGROV-1, MCF-7, MiaPaCa-2, NCI-H69, PC-3, RL and UACC-62 cells, respectively. ROC-325 induces the deacidification of lysosomes, accumulation of autophagosomes, and disrupted autophagic flux[1]. |
| In vivo | In mice bearing 786-0 RCC xenografts, ROC-325 (25, 40, and 50 mg/kg; oral) leads to significant, dose-dependent inhibition of disease progression and inhibits autophagy in vivo[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 1 mg/mL (1.99 mM), Sonication is recommended. H2O : 0.8 mg/mL (1.59 mM), Sonication is recommended. |
| Keywords | ROC-325 | ROC325 | ROC 325 | oral | lysosomes | Inhibitor | inhibit | cathepsin-D | Autophagy | Autophagosomes | Apoptosis | anticancer |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Urea | Tamoxifen | Guanidine hydrochloride | Hydroxychloroquine | Metronidazole | Formamide | Paeonol | Naringin | Alginic acid |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Autophagy Compound Library | Inhibitor Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $995.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-05-11 | |
|
VIP2Y
|
Wuhan Kejiefeng Trading Co.,Ltd
|
2026-04-17 | ||
| $1.00 |
Across Biotech Jinan Co LTD
|
2024-07-05 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY